Home›Companies›Biotech & Pharma›Matchpoint Therapeutics

Matchpoint Therapeutics Inc.

Matchpoint develops oral drugs that bind hard-to-treat protein targets in immune diseases.

Updated Nov 20, 2026·Latest SEC filing Nov 20, 2026·Suggest an edit

About Matchpoint Therapeutics

Matchpoint develops oral drugs for people with autoimmune and inflammatory diseases. Its broader discovery work also covers cancer. Its medicines attach permanently to disease-linked proteins, aiming to reach targets that other small-molecule drugs struggle to affect. It uses protein-mapping screens, machine learning and a custom compound library to find binding sites and design candidates.

Matchpoint is based in Watertown, Massachusetts, and Andre Turenne is president and chief executive officer. John O’Malley became chief medical officer in October 2026. It is privately held.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 1, 2026Nov 20, 2026$68,399,743of $150.0M target22$3.1MEquityRule 506(b)Form D ↗
Oct 5, 2022Oct 17, 2022$41,999,994of $69.9M target15$2.7MEquityRule 506(b)Form D ↗
Total, two offerings$110,399,737

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Matchpoint Therapeutics's Form D filed Nov 20, 2026.

Andre Turenne
Andre Turenne
Director; President & Chief Executive Officer
On every Form D that Matchpoint Therapeutics has filed: 2 filings, from Oct 17, 2022 to Nov 20, 2026.
BM
Brian Matesic
Director; Principal, Norwest · of Norwest, which co-led the Series B round [1][3]
First appears on the Form D that Matchpoint Therapeutics filed on November 20, 2026; on 1 of its 2 filings.
KP
Kanishka Pothula
Director; Managing Partner, Nextech
First appears on the Form D that Matchpoint Therapeutics filed on November 20, 2026; on 1 of its 2 filings.
JH
Jason Hafler
Director; Managing Director, Sanofi Ventures
On every Form D that Matchpoint Therapeutics has filed: 2 filings, from Oct 17, 2022 to Nov 20, 2026.
Jason Hafler appears on 7 Form D filings at 3 companies:
  • Icosavax, director: Oct 18, 2019 · Apr 7, 2021
  • Abcuro, director: Jan 22, 2021 (amended) · Aug 25, 2023 · Feb 19, 2025
  • Matchpoint Therapeutics, director; managing director, sanofi ventures: Oct 17, 2022 · Nov 20, 2026
BB
Bruce Booth
Chairman; Partner, Atlas Venture
On every Form D that Matchpoint Therapeutics has filed: 2 filings, from Oct 17, 2022 to Nov 20, 2026.
Bruce Booth appears on 36 Form D filings at 11 companies. Show all
  • Miragen Therapeutics, director: May 27, 2009 (2 filings) · Sep 21, 2010 · Jan 3, 2012 (amended) · Apr 24, 2012 · Jun 26, 2014 (amended) · Feb 17, 2015 · Nov 12, 2015 · Feb 14, 2017
  • Avila Therapeutics, director: Jul 31, 2009 · Jul 6, 2010 (amended)
  • Larimar Therapeutics, director: Mar 1, 2010 · Mar 2, 2010 (amended) · Jul 12, 2011 · Aug 28, 2012 · Dec 5, 2012
  • Unum Therapeutics, director: Oct 20, 2014 · Jun 25, 2015
  • Lysosomal Therapeutics, director: Feb 11, 2015 · Oct 6, 2016 · Jan 18, 2017 (amended) · Nov 7, 2019
  • Tectonic Therapeutic, director: Aug 3, 2016 · Feb 2, 2018
  • Magenta Therapeutics, director: Nov 23, 2016 · May 5, 2017 · Apr 9, 2018
  • Rodin Therapeutics, director: Sep 14, 2017
  • Miragen Therapeutics, director: Nov 22, 2017 · Aug 6, 2018
  • Vigil Neuroscience, director: Oct 5, 2020 · Jun 15, 2021 (amended) · Aug 25, 2021 · Aug 29, 2022
  • Matchpoint Therapeutics, chairman; partner, atlas venture: Oct 17, 2022 · Nov 20, 2026
DB
Daniel Becker
Director; Managing Director, Access Biotechnology
On every Form D that Matchpoint Therapeutics has filed: 2 filings, from Oct 17, 2022 to Nov 20, 2026.
DN
Donald Nicolson
Director
First appears on the Form D that Matchpoint Therapeutics filed on November 20, 2026; on 1 of its 2 filings.
Jared Cumming
Jared Cumming
Chief Scientific Officer
First appears on the Form D that Matchpoint Therapeutics filed on November 20, 2026; on 1 of its 2 filings.
John O'Malley
John O'Malley
Chief Medical Officer
First appears on the Form D that Matchpoint Therapeutics filed on November 20, 2026; on 1 of its 2 filings.

Who Invested in Matchpoint Therapeutics

Scroll table to see all columns →

AnnouncedRoundAmountLeadOther investorsOn the Form DSource
Oct 7, 2026Series B$150 millionNextech Invest; NorwestNewInvus; BB Biotech; T1D Fund; BOLD Longevity Growth.ReturningAccess Biotechnology; Atlas Venture; Sanofi Ventures; Digitalis Ventures.First sale Oct 1, 2026, 6 days before the announcement; $68,399,743 of $150,000,000 from 22 investors. [7][3]
Oct 14, 2022Launch funding$100 million——[5]

Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Why Investors Backed Matchpoint Therapeutics

Nextech pointed to MPT-062’s potential to change the management of many common immune-mediated inflammatory conditions. It saw the drug’s first-in-class mechanism as a precise oral way to address disease-causing T-cell overactivation. [3]

“MPT-062 could fundamentally change the management of many common immune-mediated inflammatory conditions with an oral medicine.”
Kanishka Pothula · Managing Partner, Nextech Invest · Series B co-lead [3]
“John brings highly relevant translational and clinical expertise in autoimmune and inflammatory diseases and an outstanding track record of building and leading effective teams to deliver innovative medicines for patients.”
Andre Turenne · Chief Executive Officer, Matchpoint Therapeutics · Chief medical officer appointment after the Series B [4]

Origin and Team

Nathanael Gray and Tinghu Zhang founded Matchpoint from Stanford University. Jianwei Che and Edward Chouchani were founders from Dana-Farber Cancer Institute. [1]

Product and Technology

Matchpoint’s view is that a lasting bond can raise potency, sharpen selectivity and sustain an effect after the drug clears. The approach can also reveal binding pockets that standard high-throughput screens miss. [1]

The Advanced Covalent Exploration platform, or ACE, uses broad screens across many proteins and focused screens on priority targets. Machine learning combines screen results with public data and protein-shape predictions. Its library includes fragments, lead-like compounds and drug-like compounds. [1]

Lead asset MPT-062 is an oral, first-in-class T-cell modulator. Clinical development is planned for 2027. [3]

A July 2025 agreement with Novartis funds an additional Matchpoint program. [3]

Use of Funds

  • Series B proceeds will move MPT-062 to clinical proof of concept and advance the wider product pipeline. [3]

Milestones

Scroll table to see all columns →

DateWhat happenedSourceCoverage
Oct 14, 2026Matchpoint appointed John O’Malley as chief medical officer.[4]—
Oct 7, 2026Matchpoint announced that Kanishka Pothula and Brian Matesic would join its board.[3]FinSMEs ↗MedPath ↗
Jul 2025Matchpoint and Novartis made an exclusive option-and-license deal for oral inhibitors aimed at several inflammatory diseases.[6]—

We wrote this summary from public statements by Matchpoint Therapeutics and its investors. It is not investment advice.

Sources

  1. CompanyMatchpoint Therapeutics website · linked above ↑
  2. CompanyMatchpoint privacy policy
  3. CompanySeries B announcement
  4. CompanyJohn O’Malley appointment announcement
  5. CompanyOfficial launch announcement
  6. CompanyNovartis agreement announcement
  7. SECMatchpoint Therapeutics Form D, filed 2026-11-20 · linked above ↑
  8. SECMatchpoint Therapeutics Form D, filed 2022-10-17 · linked above ↑
  9. SECMatchpoint Therapeutics Inc. filing history